Matches in SemOpenAlex for { <https://semopenalex.org/work/W3172912609> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W3172912609 endingPage "S26" @default.
- W3172912609 startingPage "S26" @default.
- W3172912609 abstract "Real-world evidence (RWE) generated from electronic health records (EHR) has been shown to be more relevant, timely, and representative for health technology assessment decision-making compared to evidence from clinical trials. We assessed how using EHR-derived RWE instead of published clinical trial data can impact point estimates and uncertainty ranges in cost-effectiveness estimates for advanced non-small cell lung cancer (NSCLC) therapies. We replicated a cost-effectiveness analysis of NSCLC therapies developed by the Institute for Clinical and Economic Review in 2016 (“traditional”), replacing meta-analysis-derived hazard ratios from clinical trials with RWE-derived hazard ratios for progression-free and overall survival (“RWE-enhanced”). Hazard ratios were calculated using Cox proportional hazards models adjusted for age, sex, race, practice type, performance status, and smoking history. The study used the Flatiron Health database, a nationwide (US-based) longitudinal, de-identified EHR-derived database. We compared the cost-effectiveness of immunotherapy (atezolizumab, pembrolizumab, nivolumab) vs. chemotherapy (single-agent docetaxel) in the second line of therapy. The analytic cohort included 3,492 adults with EGFR- NSCLC that progressed after first-line treatment with a platinum-based chemotherapy doublet. We report traditional and RWE-enhanced incremental cost-effectiveness ratios (ICERs) and differences in uncertainty as percent change in the size of 95% credible intervals (CIs). The traditional vs RWE-enhanced ICERs were as follows: atezolizumab — $84,000/quality-adjusted life year (QALY) vs. $138,000/QALY; nivolumab — $136,000/QALY vs. $123,000/QALY; pembrolizumab — $181,000/QALY vs $111,000/QALY. Compared to uncertainty in traditional ICERs, 95% CIs for RWE-enhanced ICERs were reduced by 37%, 69%, and 83% for atezolizumab, nivolumab, and pembrolizumab respectively. This proof-of-concept demonstrated how clinical depth, longer follow-up time, and larger sample sizes in EHR-derived data may reduce uncertainty in cost-effectiveness analysis. The approach has potential to inform dynamic value-based pricing and highlights the importance of reassessments once RWE is available." @default.
- W3172912609 created "2021-06-22" @default.
- W3172912609 creator A5010798162 @default.
- W3172912609 creator A5015248714 @default.
- W3172912609 creator A5038198314 @default.
- W3172912609 creator A5045528712 @default.
- W3172912609 creator A5064605070 @default.
- W3172912609 creator A5066041763 @default.
- W3172912609 creator A5069765198 @default.
- W3172912609 creator A5071698455 @default.
- W3172912609 creator A5079965457 @default.
- W3172912609 creator A5080199225 @default.
- W3172912609 creator A5083208432 @default.
- W3172912609 creator A5084390255 @default.
- W3172912609 date "2021-06-01" @default.
- W3172912609 modified "2023-10-15" @default.
- W3172912609 title "PCN41 Enhanced Cost-Effectiveness Analysis Using EHR Data for Real World Value" @default.
- W3172912609 doi "https://doi.org/10.1016/j.jval.2021.04.133" @default.
- W3172912609 hasPublicationYear "2021" @default.
- W3172912609 type Work @default.
- W3172912609 sameAs 3172912609 @default.
- W3172912609 citedByCount "0" @default.
- W3172912609 crossrefType "journal-article" @default.
- W3172912609 hasAuthorship W3172912609A5010798162 @default.
- W3172912609 hasAuthorship W3172912609A5015248714 @default.
- W3172912609 hasAuthorship W3172912609A5038198314 @default.
- W3172912609 hasAuthorship W3172912609A5045528712 @default.
- W3172912609 hasAuthorship W3172912609A5064605070 @default.
- W3172912609 hasAuthorship W3172912609A5066041763 @default.
- W3172912609 hasAuthorship W3172912609A5069765198 @default.
- W3172912609 hasAuthorship W3172912609A5071698455 @default.
- W3172912609 hasAuthorship W3172912609A5079965457 @default.
- W3172912609 hasAuthorship W3172912609A5080199225 @default.
- W3172912609 hasAuthorship W3172912609A5083208432 @default.
- W3172912609 hasAuthorship W3172912609A5084390255 @default.
- W3172912609 hasBestOaLocation W31729126091 @default.
- W3172912609 hasConcept C112930515 @default.
- W3172912609 hasConcept C121608353 @default.
- W3172912609 hasConcept C126322002 @default.
- W3172912609 hasConcept C143998085 @default.
- W3172912609 hasConcept C207103383 @default.
- W3172912609 hasConcept C2775949291 @default.
- W3172912609 hasConcept C2777701055 @default.
- W3172912609 hasConcept C2780030458 @default.
- W3172912609 hasConcept C2780057760 @default.
- W3172912609 hasConcept C3019080777 @default.
- W3172912609 hasConcept C44249647 @default.
- W3172912609 hasConcept C535046627 @default.
- W3172912609 hasConcept C64332521 @default.
- W3172912609 hasConcept C71924100 @default.
- W3172912609 hasConcept C72563966 @default.
- W3172912609 hasConceptScore W3172912609C112930515 @default.
- W3172912609 hasConceptScore W3172912609C121608353 @default.
- W3172912609 hasConceptScore W3172912609C126322002 @default.
- W3172912609 hasConceptScore W3172912609C143998085 @default.
- W3172912609 hasConceptScore W3172912609C207103383 @default.
- W3172912609 hasConceptScore W3172912609C2775949291 @default.
- W3172912609 hasConceptScore W3172912609C2777701055 @default.
- W3172912609 hasConceptScore W3172912609C2780030458 @default.
- W3172912609 hasConceptScore W3172912609C2780057760 @default.
- W3172912609 hasConceptScore W3172912609C3019080777 @default.
- W3172912609 hasConceptScore W3172912609C44249647 @default.
- W3172912609 hasConceptScore W3172912609C535046627 @default.
- W3172912609 hasConceptScore W3172912609C64332521 @default.
- W3172912609 hasConceptScore W3172912609C71924100 @default.
- W3172912609 hasConceptScore W3172912609C72563966 @default.
- W3172912609 hasLocation W31729126091 @default.
- W3172912609 hasOpenAccess W3172912609 @default.
- W3172912609 hasPrimaryLocation W31729126091 @default.
- W3172912609 hasRelatedWork W2626043568 @default.
- W3172912609 hasRelatedWork W2885614177 @default.
- W3172912609 hasRelatedWork W2903443301 @default.
- W3172912609 hasRelatedWork W2911229154 @default.
- W3172912609 hasRelatedWork W2957427793 @default.
- W3172912609 hasRelatedWork W3081615089 @default.
- W3172912609 hasRelatedWork W3118442307 @default.
- W3172912609 hasRelatedWork W3134678141 @default.
- W3172912609 hasRelatedWork W3136123238 @default.
- W3172912609 hasRelatedWork W3154458198 @default.
- W3172912609 hasVolume "24" @default.
- W3172912609 isParatext "false" @default.
- W3172912609 isRetracted "false" @default.
- W3172912609 magId "3172912609" @default.
- W3172912609 workType "article" @default.